文章基本信息

标题：Buprenorphine unobserved “home” induction: a survey of Ontario’s addiction physicians
本地全文：下载
作者：Anita Srivastava ; Meldon Kahan ; Pamela Leece 等
期刊名称：Addiction Science & Clinical Practice
电子版ISSN：1940-0640
出版年度：2019
卷号：14
期号：1
页码：1-8
DOI：10.1186/s13722-019-0146-4
出版社：BioMed Central
摘要：Ontario patients on opioid agonist treatment (OAT) are often prescribed methadone instead of buprenorphine, despite the latter’s superior safety profile. Ontario OAT providers were surveyed to better understand their attitudes towards buprenorphine and potential barriers to its use, including the induction process. We used a convenience sample from an annual provincial conference to which Ontario physicians who are involved with OAT are invited. Based on 85 survey respondents (out of 215 attendees), only 4% of Ontario addiction physicians involved in OAT routinely used unobserved “home” buprenorphine induction: 59% of physicians felt that unobserved induction was risky because it was against “the guidelines” and 66% and 61% respectively believed that unobserved “home” induction increased the risk of diversion and of precipitated withdrawal. Ontario addiction physicians largely report following the traditional method of bringing in patients for observed in-office buprenorphine induction: they expressed fear of precipitated withdrawal, diversion, and going against clinical guidelines. The hesitance in using unobserved induction may explain, in part, Ontario’s reliance on methadone.
关键词：Buprenorphine ; Physician survey ; Home induction ; Unobserved